Clinical Trial Update: Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update examining zimberelimab with or without domvanalimab in resectable MSI-H/dMMR gastric and gastroesophageal junction cancers; study currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Domvanalimab (domvanalimab)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer | Phase 2 | Status: RECRUITING